1 min readCentre for Proteomic & Genomic Research and CapitalBio Announce Collaboration
Under the agreement, CB will grant CPGR access to its complete microarray assay platform, including biochip readers, together with a range of proprietary DNA microarrays. In return, CPGR will form a reference centre for CB microarray applications in Southern Africa, including custom-designed applications for tuberculosis (TB) strain typing and drug resistance testing.
“The association between CapitalBio and the CPGR represents a major step forward our efforts to bring better diagnostics to the emerging and developing lands in Africa” said Professor Jing Cheng, CEO of CapitalBio. “CapitalBio has worked closely with the National Tuberculosis Reference Laboratory of the China Center for Disease Control and Prevention to provide assays of international relevance, and we see enormous potential for the worldwide use of this technology to bring effective diagnostics to TB sufferers.”
“The CPGR was created with a vision of establishing a modern, world class, high throughput biological research facility,” said the Minister of Science and Technology of South Africa, the Honourable Mosibudi Mangena. “Such delivery is central to our National Biotechnology Strategy – where we are seeking to develop a globally competitive sector with products and services that are world class but focus primarily on local needs. CPGR’s collaboration with CapitalBio is a positive development towards that goal.”